MRMD— MARIMED INC.

MaterialsPharmaceuticals$27M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$159.8M+1.3%	$157.7M+6.1%	$148.6M+10.9%	$134.0M
Cost of revenue	$101.9M+7.2%	$95.1M+15.0%	$82.7M+18.0%	$70.1M
Gross profit	$57.9M-7.6%	$62.6M-5.0%	$65.9M+3.1%	$64.0M
Personnel	$28.5M+5.4%	$27.1M+19.7%	$22.6M+57.0%	$14.4M
Marketing and promotion	$4.0M-40.8%	$6.7M+12.3%	$6.0M+60.0%	$3.7M
General and administrative	$26.1M+2.0%	$25.6M+15.8%	$22.1M+6.7%	$20.7M
Acquisition-related and other	$486K-48.9%	$951K+36.8%	$695K-27.7%	$961K
Bad debt expense (income)	$1.6M+570.8%	-$336K-384.7%	$118K-96.9%	$3.8M
Total operating expenses	$60.7M+1.2%	$60.0M+16.4%	$51.5M+18.2%	$43.6M
(Loss) income from operations	-$2.8M-208.1%	$2.6M-81.9%	$14.4M-29.4%	$20.4M
Interest expense	-$7.5M-8.0%	-$6.9M+24.4%	-$9.2M-442.5%	-$1.7M
Interest income	$177K+55.3%	$114K-57.8%	$270K-71.8%	$959K
Other expense, net	-$717K-1334.0%	-$50K+96.9%	-$1.6M-1187.4%	-$127K
Total interest and other expense, net	-$8.0M-16.9%	-$6.9M+67.2%	-$21.0M-2336.8%	-$861K
Loss before income taxes	-$10.9M-154.3%	-$4.3M+35.2%	-$6.6M-133.8%	$19.5M
Provision for income taxes	$3.6M-56.0%	$8.2M-13.3%	$9.4M+59.7%	$5.9M
Net loss	-$14.5M-16.3%	-$12.4M+22.3%	-$16.0M-217.6%	$13.6M
Less: Net income attributable to noncontrolling interests	$28K-24.3%	$37K+54.2%	$24K-83.6%	$146K
Net loss attributable to common stockholders	-$14.5M-16.2%	-$12.5M+22.2%	-$16.0M-219.0%	$13.5M
Basic (in dollars per share)	-$0.04-33.3%	-$0.03+25.0%	-$0.04-200.0%	$0.04
Diluted (in dollars per share)	-$0.04-33.3%	-$0.03+25.0%	-$0.04-200.0%	$0.04
Basic (in shares)	390.1M+2.9%	379.2M+4.3%	363.4M+7.6%	337.7M
Diluted (in shares)	390.1M+2.9%	379.2M+4.3%	363.4M-4.4%	380.3M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.